Karo Bio forced to abandon Phase III-stage eprotirome

Karo Bio's future looks uncertain following news that it is dropping its Phase III-stage drug candidate eprotirome after a preclinical study demonstrated "unwanted effects following long-term exposure". As a result, the planned spin-off of the company's preclinical operations into a separate entity will not proceed.